MOVE Medacta Group

Medacta Celebrates Expansion into New Distribution Facility in the US

Medacta Group SA / Key word(s): Expansion
Medacta Celebrates Expansion into New Distribution Facility in the US

05.04.2023 / 19:00 CET/CEST


MEDIA RELEASE

Medacta Celebrates Expansion into New Distribution Facility in the US

CASTEL SAN PIETRO, 5 April 2023 – Medacta, a Swiss company featuring innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgeries, announces the grand opening of its expanded distribution facility located in Memphis, TN, which became operational on March 6, 2023.

"Our presence in the United States continues to grow. This new facility, along with two recent major plant expansions at our Swiss Headquarters, represents a positive step forward in our commitment to providing reliable service to our customers so they can serve their patients safely and effectively," stated Francesco Siccardi, Chief Executive Officer of Medacta International. "Moreover, we strategically invested in strengthening our supply chain by increasing surgical instrument sets and implant stock to serve new customers, pre-empt possible shortages, capture market opportunities, and sustainably support our continuing growth."

Through this expansion, Medacta Americas Operations (MAO) will now occupy over 108,000 square feet in this newly constructed facility, which will support all elements of operations and distribution from a central location. This expanded footprint allows for greater stocking levels and on-hand inventory and features offices, meeting spaces, and a demonstration room to accommodate tours and training. It also works in complete synergy with the Nashville, TN headquarters of Medacta USA (MUSA) by providing cutting-edge medical devices to surgeons throughout the United States.

“Medacta America Operations represents a strong step forward for Medacta as we grow our presence throughout the United States,” shared Shawn McIntyre, General Manager of MAO. “We are incredibly proud that we navigated this transition with no service interruptions to the field, and we look forward to the opportunities ahead.”

Following its first FDA product clearance and US surgical case in 2008, MUSA quickly outgrew its distribution center in Camarillo, CA, prompting a relocation of its headquarters and distribution to a 7,500 square foot location in Chicago, IL. In 2015, MUSA moved to its former Memphis facility, with an expanded footprint of 22,500 feet. The tremendous growth of over 100,000 square feet in distribution and operations capacity clearly demonstrates Medacta’s commitment to equipping orthopedic surgeons with the products needed to improve patient well-being. 

Additional information about Medacta may be found by visiting .


Contact 

Medacta International SA
Gianluca Olgiati     
Senior Director Global Marketing  
Phone: 0

 

About Medacta
Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with expert surgeons globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 50 countries. Follow Medacta on , , , and .


Additional features:

File:


End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone:
E-mail:
Internet:
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1601585

 
End of News EQS News Service

1601585  05.04.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1601585&application_name=news&site_id=research_pool
EN
05/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medacta Group

Maria Vara ... (+3)
  • Maria Vara
  • Oscar Haffen Lamm
  • Valliant Campagne

Suspension of coverage

From 2nd of June we are suspending coverage of companies below due to a reallocation of resources. Our prior estimates should no longer be used as an indicator for the company moving forward.INNATE PHARMAINVENTIVAMEDACTAMEDARTISONWARD MEDICALVALNEVA

Maria Vara
  • Maria Vara

Medacta: model update - Buy rating reiterated, unchanged CHF160 PT

We update our model following the publication of the company's annual report. No changes have been applied to our revenue forecast as FY 2024 results and 2025 guidance are aligned with our estimates. On the P&L, we have softened our S&M expenses expectation as these stood more towards 35.5%

 PRESS RELEASE

Medacta publishes 2025 Annual General Meeting invitation

Medacta Group SA / Key word(s): AGMEGM Medacta publishes 2025 Annual General Meeting invitation 08.04.2025 / 10:00 CET/CEST Press Release                     Medacta publishes 2025 Annual General Meeting invitation  CASTEL SAN PIETRO, 8 April 2025 – Medacta Group SA (“Medacta”, SIX:MOVE) published today the invitation to the Annual General Meeting (“AGM”) which will take place on Wednesday, 7 May 2025 at 11.00 a.m. at the Group premises in Via alla Rossa 6, Rancate, Switzerland. Shareholders can register to attend the Annual General Meeting in person but will also be abl...

Maria Vara
  • Maria Vara

Medacta: Exceptional FY2024 to fuel sustainable growth, adj. EBITDA hi...

Medacta reported preliminary unaudited FY 2024 revenue in early February; hence, the EUR590.6m figure was not a surprise. Nonetheless, we may highlight again that all four business lines delivered above the market growth with double-digit cc gains with a broad base geographical contribution. Gross

Maria Vara
  • Maria Vara

Medacta: expanding SportsMed footprint with Parcus Medical acquisition

Medacta expands its SportMeds footprint by acquiring Parcus Medical, a distinguished player with a diverse product family in sports medicine spanning the shoulder, knee, hip, and foot & ankle, with FY2024 unaudited revenues of USD16m. The acquisition not only expands Medacta's offering but also

ResearchPool Subscriptions

Get the most out of your insights

Get in touch